Morningstar

Thermo Fisher 4Q Profit Rises as Biopharma Spending Rebounds

Provided by Dow Jones

By Nicholas G. Miller 




  Thermo Fisher reported higher fourth-quarter profit and revenue as biopharmaceutical research spending bounces back following a pause early last year. 



  The company posted net income of $1.96 billion, or $5.21 a share, up from $1.83 billion, or $4.78 a share, the year prior. 



  Adjusted earnings were $6.57 a share. Analysts polled by FactSet expected $6.45 a share. 



  Revenue rose 7% to $12.21 billion. Wall Street expected $11.95 billion. 



  Analysts have said that while uncertainty around tariffs and drug pricing hurt biopharmaceutical research spending earlier last year, the environment improved by the end of 2025, which is a boost to life sciences companies like Thermo Fisher. 



  The pharmaceutical industry has received better visibility through deals with the Trump administration while the Food and Drug Administration has approved a significant number of new drugs. 





  Write to Nicholas G. Miller at nicholas.miller@wsj.com. 





  (END) Dow Jones Newswires



  January 29, 2026 06:34 ET (11:34 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
3 Stocks to Sell and 3 Stocks to Buy for October
 
Plus, lessons from September’s stock market activity. 
 
 
David Sekera, CFA and Susan Dziubinski 
 
 
 
The 10 Best Companies to Invest in Now
 
The stocks of these high-quality companies look cheap today. 
 
 
Tori Brovet 
 
 
 
14 Elite Funds and ETFs, and 5 Popular Funds That Just Missed the Mark
 
Russ Kinnel shares investment ideas from his annual Thrilling Funds list and discusses how he screens for quality investments in a sea of options. 
 
 
Russel Kinnel and Ivanna Hampton 
 
 
 
3 Stocks to Invest In With More Room to Run
 
These stocks are up significantly in 2026, yet still look undervalued today. 
 
 
Susan Dziubinski 
 
 
 
Why Cash Is Still King for Short-Term Goals
 
Longer-term bonds are more attractive than they’ve been in a long time, but they still carry a fair amount of risk. 
 
 
Amy C. Arnott, CFA 
 
 
 
 

			Sponsor Center